All In Biotech

Free tool

FAERS Monitor: Lotrimin Af

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020889 or its brand name (Lotrimin Af, Clotrimazole). Reports on generic versions are filed under their own applications.

Reports

1,437

Serious

659

46% of reports

Hospitalization

314

Death reported

86

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • vulvovaginal burning sensation242
  • drug ineffective180
  • vulvovaginal pain79
  • condition aggravated75
  • vulvovaginal pruritus73
  • off label use71
  • drug interaction58
  • vulvovaginal discomfort47
  • constipation46
  • abdominal pain43
  • vaginal haemorrhage42
  • hypersensitivity41
  • international normalised ratio increased41
  • pain41
  • sepsis41

Reports by year received

View as table
YearReports
200411
200511
200618
20075
200828
200947
201031
201141
201294
201356
201432
201520
201650
201751
201844
201957
202098
2021114
2022140
202394
2024107
2025136
2026152

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,722 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vulvovaginal burning sensationSignal242604.2537.1139,421
vulvovaginal painSignal79244.0196.618,573
vulvovaginal pruritusSignal73214.0170.915,050
vulvovaginal discomfortSignal47157.3118.67,070
international normalised ratio increasedSignal4121.115.6764
vaginal haemorrhageSignal4214.210.5502
sepsisSignal415.44.0143
drug interactionSignal585.44.2202
condition aggravatedSignal753.62.9141
hypersensitivitySignal413.22.462
constipationSignal463.12.364
abdominal painSignal432.72.045
drug ineffective1802.01.795
off label use711.20.92
pain411.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.